These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 35544877)
1. [A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Córdoba, Argentina]. Aballay LR; Coquet JB; Scruzzi GF; Haluszka E; Franchini G; Carreño P; Raboy E; Román MD; Niclis C; Balangero M; Altamirano N; Barbás MG; López L Cad Saude Publica; 2022; 38(4):ES219821. PubMed ID: 35544877 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic. Schonfeld D; Fernández H; Ramírez J; Acosta D; Becerra J; Wettstein M; Strella T; Vaccaro M; Arias S; Rodríguez Calvo V; Neme R; Pérez-Chada D PLoS One; 2022; 17(3):e0263679. PubMed ID: 35286328 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays. Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N; Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976 [TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP; Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702 [TBL] [Abstract][Full Text] [Related]
5. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F; Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811 [TBL] [Abstract][Full Text] [Related]
6. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil. Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142 [TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States. Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144 [TBL] [Abstract][Full Text] [Related]
8. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic. Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP; Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439 [TBL] [Abstract][Full Text] [Related]
10. Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays. Tuite AR; Fisman D; Abe KT; Rathod B; Pasculescu A; Colwill K; Gingras AC; Yi QL; O'Brien SF; Drews SJ Microbiol Spectr; 2022 Feb; 10(1):e0256321. PubMed ID: 35196819 [TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation. Martinez-Acuña N; Avalos-Nolazco DM; Rodriguez-Rodriguez DR; Martinez-Liu CG; Galan-Huerta KA; Padilla-Rivas GR; Ramos-Jimenez J; Ayala-de-la-Cruz S; Cienfuegos-Pecina E; Diaz-Chuc EA; Cazares-Tamez R; Flores-Arechiga A; Perez-Chavez F; Arellanos-Soto D; Lozano-Sepulveda SA; Garza-Gonzalez E; Treviño-Garza C; Montes-de-Oca-Luna R; Lee-Gonzalez AB; de-la-O-Cavazos ME; Rivas-Estilla AM Viruses; 2021 Jun; 13(7):. PubMed ID: 34202849 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620 [TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. Ristić M; Milosavljević B; Vapa S; Marković M; Petrović V PLoS One; 2021; 16(7):e0254516. PubMed ID: 34242377 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. Tönshoff B; Müller B; Elling R; Renk H; Meissner P; Hengel H; Garbade SF; Kieser M; Jeltsch K; Grulich-Henn J; Euler J; Stich M; Chobanyan-Jürgens K; Zernickel M; Janda A; Wölfle L; Stamminger T; Iftner T; Ganzenmueller T; Schmitt C; Görne T; Laketa V; Olberg S; Plaszczyca A; Cortese M; Bartenschlager R; Pape C; Remme R; Huzly D; Panning M; Weigang S; Giese S; Ciminski K; Ankerhold J; Kochs G; Schwemmle M; Handgretinger R; Niemeyer CM; Engel C; Kern WV; Hoffmann GF; Franz AR; Henneke P; Debatin KM; Kräusslich HG JAMA Pediatr; 2021 Jun; 175(6):586-593. PubMed ID: 33480966 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941 [TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study. Murhekar MV; Bhatnagar T; Thangaraj JWV; Saravanakumar V; Santhosh Kumar M; Selvaraju S; Rade K; Kumar CPG; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chakraborty D; Chopra V; Das D; Devi KR; Dwivedi GR; Jain A; Khan SMS; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Ramesh T; Rangaraju C; Turuk J; Yadav S; Bhargava B; PLoS Med; 2021 Dec; 18(12):e1003877. PubMed ID: 34890407 [TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study. Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747 [TBL] [Abstract][Full Text] [Related]